Tirzepatide vs Semaglutide: Direct Comparison of Weight Loss, Side Effects, and Cost

The basics: what are these drugs?

Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk. It activates one receptor type — the GLP-1 receptor — mimicking the natural gut hormone GLP-1. It is sold as:

• Ozempic (injection, 0.5–2 mg/week, approved for type 2 diabetes)
• Wegovy (injection, 2.4 mg/week, approved for obesity/weight management)
• Rybelsus (oral, 7–14 mg/day, approved for type 2 diabetes)

Tirzepatide is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. It activates two receptor types — both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. It is sold as:

• Mounjaro (injection, 2.5–15 mg/week, approved for type 2 diabetes)
• Zepbound (injection, 2.5–15 mg/week, approved for obesity/weight management)

Mechanism differences: one receptor vs two

The dual-agonism of tirzepatide is the key mechanistic distinction. GIP is a distinct hormone from GLP-1 that has overlapping but non-identical effects on the metabolic system.

GIP is secreted by K-cells in the upper small intestine and:

• Augments insulin secretion (same direction as GLP-1, additive effect)
• Acts on adipose tissue to modulate fat storage
• Has direct effects on brain appetite circuits that may complement GLP-1 effects

The combination of GLP-1 + GIP activation appears to produce greater appetite suppression and metabolic effects than GLP-1 alone in clinical trials. This is the proposed explanation for tirzepatide's superior weight loss outcomes.

Head-to-head weight loss data

SURMOUNT-5 trial (2024): This is the only direct head-to-head RCT comparing tirzepatide (Zepbound) to semaglutide (Wegovy) in obese adults without T2D. Results at 72 weeks:

The difference is substantial: tirzepatide produced approximately 47% more relative weight loss than semaglutide. This is not a trivial difference — it represents a meaningful distinction in clinical outcomes for most patients.

Indirect comparisons (cross-trial):

These trials used similar populations (obese adults without T2D) but different designs, so they are not formally head-to-head. SURMOUNT-5 provides the more reliable direct comparison.

Side effect comparison

Both drugs share a similar GI side effect profile — this is a class effect of GLP-1 agonism. A full GLP-1 side effects comparison covers the data from each drug's Phase 3 trial.

Data from respective Phase 3 trials. Direct trial-to-trial comparison has limitations.

Tirzepatide appears to have a modestly better tolerability profile despite superior efficacy — lower reported nausea and vomiting rates than semaglutide in their respective trials. This finding has been discussed in terms of the GIP component potentially mitigating some GLP-1-mediated GI effects.

Tirzepatide class-specific concerns: As a dual agonist, tirzepatide carries the same thyroid, pancreatic, and gallbladder warnings as semaglutide, since GLP-1 agonism is the shared mechanism. No new safety signals unique to tirzepatide have been identified in Phase 3 data.

FDA-approved indications

Semaglutide has substantially more approved indications reflecting its longer market history and completed outcome trials. This matters for insurance coverage and off-label use justification.

Price and insurance coverage

Tirzepatide has a lower list price by approximately $290/month, though real-world out-of-pocket costs are similar with savings programmes.

Which to choose: a practical framework

Neither drug is universally "better" — the choice depends on patient-specific factors:

Choose semaglutide if

• You have cardiovascular disease (SELECT trial shows 20% MACE reduction — the only GLP-1 drug with completed CV outcome data for obesity)
• You have chronic kidney disease (FLOW trial data established renal protection)
• Your insurance covers Wegovy but not Zepbound (common due to semaglutide's longer approval history)
• You prefer a more established safety record (longer post-market surveillance)

Choose tirzepatide if

• Maximising weight loss is the priority (consistent 5–7 percentage point advantage over semaglutide)
• Tolerability is a concern (appears to have modestly lower GI side effects in trials)
• You are starting from a higher body weight where total percentage loss matters more

For T2D patients: Both drugs are effective for glucose management. Tirzepatide shows greater HbA1c reduction (average ~2.3% vs ~1.8% for semaglutide 1 mg in SURPASS vs SUSTAIN cross-trial comparison).

A note on brand vs compounded versions

Both semaglutide and tirzepatide are currently available as compounded versions through §503A pharmacies, at significantly lower prices:

• Compounded semaglutide: $147–$297/month (varies by provider and dose)
• Compounded tirzepatide: $299–$449/month (varies by provider and dose)

Compounded versions are patient-specific, not FDA-approved, and carry regulatory risk given the ongoing FDA enforcement activity around compounders. See our articles on compounded vs brand semaglutide and cheap GLP-1 alternatives for current detail.

Summary

Tirzepatide produces approximately 47% more relative weight loss than semaglutide in the only head-to-head RCT (SURMOUNT-5). Both drugs have similar but not identical side effect profiles — tirzepatide appears modestly better tolerated despite greater efficacy. Semaglutide has a longer market history, more completed outcome trials, and more approved indications. The choice depends on weight loss goals, existing cardiovascular or kidney disease, insurance formulary, and cost considerations.

For dosing specifics, see the Wegovy dose escalation schedule and Zepbound dose escalation schedule. For head-to-head pricing and formulary access, see our article comparing Mounjaro vs Zepbound.